Figure 3: Western immunoblot of BRAF V600E, p-ERK1/2, AKT/mTOR and BONNA-12 proliferation assay. | Scientific Reports

Figure 3: Western immunoblot of BRAF V600E, p-ERK1/2, AKT/mTOR and BONNA-12 proliferation assay.

From: Potential role of AKT/mTOR signalling proteins in hairy cell leukaemia: association with BRAF/ERK activation and clinical outcome

Figure 3

(A) Western immunoblot indicating BRAFV600E, AKT/mTOR pathway components and p-ERK1/2 protein expression in 7 HCL tumour samples. All experiments have been performed at least three times and representative results of one experiment are shown. (B) Cell proliferation assay of BONNA-12 cells carrying the wild type or V600E mutant BRAF gene before and after rapamycin treatment (500 nM) for 48 hrs. (C) Western immunoblot indicating BRAF V600E, p-ERK1/2, AKT /mTOR cascade protein expression in BONNA-12 cells carrying the wild-type or V600E mutant BRAF gene before and after rapamycin treatment.

Back to article page